Skip to content

Zai Lab

US · ZLAB #2554 by market cap Listed 2017
21.03 -0.89 -4.06%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 4.91 Expensive vs history 96th percentile
5-year average 3.35 · #385 of 514 in Biotechnology
P/E ratio -13.67 Cheap vs history 15th percentile
5-year average -9.10 · forward -13.20
P/S ratio 6.26 Cheap vs history 23rd percentile
5-year average 13.12 · forward 6.03 · #134 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Zai Lab (ZLAB) 2.36B -11.68 4.20 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value34.31 Economic moatNone UncertaintyHigh

Trading 63.1% below Morningstar's fair value estimate.

Fair value

At face value, Zai Lab Ltd looks inexpensive, following a substantial price decline over the past year. To account for the risk of a possible value trap, we have capped its rating at 3 stars. The stock currently trades at a 28% discount to our quantitative fair value estimate of $34.31 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 4.7, which falls in the bottom 45% compared with peers globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.

The company's liquidity is an additional encouraging factor. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. The firm's median trading volume over the past 60 days, a core component of liquidity, falls in the top 20% compared with global peers. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. This characteristic further promotes our favorable price/fair value ratio.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Zai Lab discussion 0 comments

Add a comment